G. Ali, M. Altareb, N. Chaudhri, F. Alfraih
{"title":"Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with a Donor and Recipient Infected with SARS-CoV-2 Infection","authors":"G. Ali, M. Altareb, N. Chaudhri, F. Alfraih","doi":"10.4103/joah.joah_10_21","DOIUrl":null,"url":null,"abstract":"The current coronavirus disease 2019 (COVID 19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS CoV 2), has impacted many facets of hematopoietic cell transplantation (HCT) in both developed and developing countries. The full impact of the COVID 19 pandemic, caused by the SARS CoV 2, on the field of hematopoietic cell transplantation (HCT) is unknown. Here, we report a rare case of a 21-year-old male patient known to have chronic myeloid leukemia (CML) with progression to T-cell lymphoblastic lymphoma as extramedullary blast crisis of CML. The patient was treated by pediatric chemotherapy regimen then. He underwent haploidentical stem cell transplantation. Posttransplantation, on day +7, he developed SARS-CoV-2 after receiving stem cell graft from a donor who was diagnosed with SARS-CoV-2 on the day of stem cells harvesting. The case elaborates complications and outcome of a patient receiving stem cell transplant from a donor with SARS-CoV-2 infection.Copyright © 2023 Journal of Applied Hematology Published by Wolters Kluwer - Medknow.","PeriodicalId":36501,"journal":{"name":"Journal of Applied Hematology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/joah.joah_10_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
感染SARS-CoV-2的供体和受体单倍体造血干细胞移植的疗效
当前由严重急性呼吸系统综合征冠状病毒2 (SARS CoV 2)引起的冠状病毒病2019 (COVID - 19)大流行,对发达国家和发展中国家造血细胞移植(HCT)的许多方面都产生了影响。由SARS冠状病毒引起的COVID - 19大流行对造血细胞移植(HCT)领域的全面影响尚不清楚。在此,我们报告一例罕见的21岁男性慢性髓性白血病(CML)进展为t细胞淋巴母细胞淋巴瘤的CML髓外细胞危象。患者采用儿科化疗方案治疗。他接受了单倍体干细胞移植。移植后的第7天,他接受了在干细胞收获当天被诊断为SARS-CoV-2的供者的干细胞移植后,出现了SARS-CoV-2。该病例详细介绍了接受SARS-CoV-2供体干细胞移植的患者的并发症和结果。版权所有©2023《应用血液学杂志》,Wolters Kluwer - Medknow出版。
本文章由计算机程序翻译,如有差异,请以英文原文为准。